---
title: "Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294061154.md"
description: "A third program from the company has entered the clinical development phase using the FORCE platform. The objective is to achieve significant functional improvement in a rare neuromuscular disease. This initiative underscores the company's commitment to addressing rare diseases through innovative solutions."
datetime: "2026-07-28T11:34:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294061154.md)
  - [en](https://longbridge.com/en/news/294061154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294061154.md)
generator: "portal-rs"
---

# Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

A third program from the company has entered the clinical development phase using the FORCE platform. The objective is to achieve significant functional improvement in a rare neuromuscular disease. This initiative underscores the company's commitment to addressing rare diseases through innovative solutions.

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)

## Related News & Research

- [Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy](https://longbridge.com/en/news/298319347.md)
- [Dyne Therapeutics (NASDAQ:DYN) CEO Sells 5,658 Shares](https://longbridge.com/en/news/298366265.md)
- [Morgan Stanley Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)](https://longbridge.com/en/news/298454669.md)
- [Novartis RNA drug falls short in rare muscle disease study](https://longbridge.com/en/news/298589584.md)
- [USA Rare Earth (USAR) Stock Looks Below Fair Value After Pullback](https://longbridge.com/en/news/298659171.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**